{
  "abstract": "Cancer-related pain affects more than 70% of patients with advanced cancer and it is mediated by tumor invasion and inflammatory cytokine-induced neural sensitization. Anticancer therapies may transiently exacerbate pain through treatment-related inflammatory responses. Amivantamab, an EGFR-MET bispecific antibody approved for EGFR-mutated non-small cell lung cancer, commonly causes infusion-related reactions (IRRs), typically with flushing or respiratory symptoms. We report a case of a 70-year-old woman with EGFR-mutated lung adenocarcinoma who developed a reproducible, transient exacerbation of pre-existing cancer-related pain during initial amivantamab infusions without any systemic abnormalities or clear evidence of radiologic progression. This suggests that acute pain flare is an atypical manifestation of amivantamab-induced IRR.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "name": "Ryutaro Yamaguchi"
    },
    {
      "name": "Yosuke Tamura"
    },
    {
      "name": "Yuki Asai"
    },
    {
      "name": "Kazuhiro Takezaki"
    },
    {
      "name": "Akira Yura"
    },
    {
      "name": "Hideaki Kawaguchi"
    },
    {
      "name": "Yasuyuki Shimazu"
    },
    {
      "name": "Masahiro Arai"
    },
    {
      "name": "Sho Mitsuya"
    },
    {
      "name": "Tomoya Funamoto"
    },
    {
      "name": "Hiroyuki Tsuji"
    },
    {
      "name": "Ninso Matsunaga"
    },
    {
      "name": "Kenjiro Tsuruoka"
    },
    {
      "name": "Takahiko Nakamura"
    },
    {
      "name": "Soichiro Ikeda"
    },
    {
      "name": "Yasuhito Fujisaka"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a6yzp5ys3jq4d.bib",
  "cited_by": 1,
  "doi": "10.2169/internalmedicine.7268-26",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_article",
  "id": "a6yzp5ys3jq4d",
  "issns": [
    "1349-7235",
    "0918-2918"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/general"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7167246377",
  "pdf_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-04",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/a6yzp5ys3jq4d.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "10.2169/internalmedicine.7268-26",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction",
  "title_text": "Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/a6yzp5ys3jq4d",
  "venue": "Internal Medicine",
  "versions": []
}